OUTLOOK THERAPEUTICS, INC. Selling, General and Administrative Expense
OUTLOOK THERAPEUTICS, INC. (OTLK) reported Selling, General and Administrative Expense of $7.55 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-18
- OUTLOOK THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $7.55M, a 21.99% decline year-over-year.
- OUTLOOK THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $9.50M, a 19.04% increase year-over-year.
- OUTLOOK THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $8.61M, a 27.91% decline year-over-year.
- OUTLOOK THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $10.33M, a 0.26% decline year-over-year.
- OUTLOOK THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2025 was $39.94M, a 33.39% increase from fiscal 2024.
- OUTLOOK THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2024 was $29.94M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.55M 10-Q · filed 2026-08-18 | $17.06M derived: sum of 2 quarters · filed 2026-08-18 | $25.67M 10-Q · filed 2026-08-18 | $36.00M derived: sum of 4 quarters · filed 2026-08-18 |
| 2026-03-31 | $9.50M 10-Q · filed 2026-05-15 | $18.12M 10-Q · filed 2026-05-15 | $28.44M derived: sum of 3 quarters · filed 2026-05-15 | $38.12M derived: sum of 4 quarters · filed 2026-08-18 |
| 2025-12-31 | $8.61M 10-Q · filed 2026-02-17 | $18.94M derived: sum of 2 quarters · filed 2026-02-17 | $28.62M derived: sum of 3 quarters · filed 2026-08-18 | $36.60M derived: sum of 4 quarters · filed 2026-08-18 |
| 2025-09-30 | $10.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-19 | $20.01M derived: sum of 2 quarters · filed 2026-08-18 | $27.99M derived: sum of 3 quarters · filed 2026-08-18 | $39.94M 10-K · filed 2025-12-19 |
| 2025-06-30 | $9.68M 10-Q · filed 2026-08-18 | $17.66M derived: sum of 2 quarters · filed 2026-08-18 | $29.61M 10-Q · filed 2026-08-18 | $39.97M derived: sum of 4 quarters · filed 2026-08-18 |
| 2025-03-31 | $7.98M 10-Q · filed 2026-05-15 | $19.93M 10-Q · filed 2026-05-15 | $30.29M derived: sum of 3 quarters · filed 2026-05-15 | $38.65M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $11.95M 10-Q · filed 2026-02-17 | $22.30M derived: sum of 2 quarters · filed 2026-02-17 | $30.66M derived: sum of 3 quarters · filed 2026-02-17 | |
| 2024-09-30 | $10.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-19 | $18.72M derived: sum of 2 quarters · filed 2025-12-19 | $29.94M 10-K · filed 2025-12-19 | |
| 2024-06-30 | $8.36M 10-Q · filed 2025-08-14 | $19.59M 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |